Get started
Citius Pharmaceuticals, Inc.Citius Pharmaceuticals, Inc.Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

CTXR trade ideas

CTXR 2M Long Termtest Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to people suffering from hemorrhoids, NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome, and I/ONTAK, a protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL). The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.
NASDAQ:CTXRLong
by TheCryptoChartWhisperer
2
CTXR 15Min Scalper's editiontest Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.
NASDAQ:CTXRLong
by TheCryptoChartWhisperer
CTXR Chart Looks Nice + Upcoming CatalystAnalyzing volume using 1hr candles. Take Aways: 1) Consolidating b/t 1.86 to 1.97 -> Needs to break over 2.02 for uptrend confirmation per fib levels 2) Price targets are 2.22 & 2.40 -> take 50% profit at 2.22 and let rest ride 2) Set SL @ 1.86 for a tight SL, @ 1.58 for loose, and @ 1.35 if you're portfolio can handle the choppiness we're in 3) Mino-lok goes for FDA approval late April. Nearest competition $CRMD failed approval roughly a month ago and dropped 60% on the news so please do not go full port on this This is not financial advice and should only be used for entertainment purposes. Do your own due diligence.
NASDAQ:CTXRLong
by nemiDD
Wave 5 Pullback A-B-> C??? Strong Resistance 2.7-2.89Short term wise, I am seeing a downward post Wave 5 A-B-C correction. Until "C" is confirmed, unable to see where is the Profit Target. First support zone SP2, if failed to hold, will continue to dip to SP1. If SP1 does not hold, watch the ultimate Life Line bottom. Very cheap to enter at Life Line. Extremely strong resistance area $2.7-$2.89. It rejects immediately at $2.89. Conclusion: Enter at support area SP2, SP1, and exit and take profit at RS1.
NASDAQ:CTXR
by OnePointScalp
$CTXR Announces Closing of $76.5M Registered Direct OfferingCitius Pharmaceuticals Announces $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules. today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the purchase of an aggregate of 50,830,566 shares of its common stock and accompanying warrants to purchase up to an aggregate of 25,415,283 shares of its common stock, at a purchase price of $1.505 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules. The warrants have an exercise price of $1.70 per share, will be immediately exercisable, and will expire five years from the issue date. finance.yahoo.com Citius Pharmaceuticals Announces Closing of $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules finance.yahoo.com
NASDAQ:CTXR
by AlenCiken